The purpose of this study is to explore the efficacy analysis of PMT and CDT before and after the treatment of high-risk APE, the changes of serum BNP, TnI and DFR levels and clinical application value, so as to provide help for the diagnosis and treatment of clinical APE. The gene discussed is NPPB; the disease is apparent mineralocorticoid excess.